Helius Medical Technologies, Inc. (NASDAQ: HSDT) is witnessing a notable surge of 22.83% during the pre-market trading session, currently valued at $6.95 per share. This positive momentum in HSDT shares can be directly attributed to the recent announcement of a strategic partnership.
Today, Helius Medical (HSDT) and Lovell Government Services announced their partnership. Through this partnership, HSDT will be able to provide government healthcare systems with access to its Portable Neuromodulation Stimulator (“PoNS”). PoNS can be used to treat gait impairments in people with mild to moderate symptoms of multiple sclerosis (MS) in conjunction with physical therapy.
Helius Medical and Lovell’s partnership will make the revolutionary point-of-care technology (PONS) more widely available. Through its Multiple Sclerosis Centers of Excellence, the Department of Veterans Affairs (VA) is dedicated for enhancing the quality of life for veterans who suffer from multiple sclerosis.
After receiving PoNS Therapy for 14 weeks, 100% of MS patients had clinically significant improvements in their gait, according to a real-world efficacy study. PoNS has the potential to completely transform the way that veterans and their families are treated, as the VA receives reports on over 28,000 MS cases each year.
The VA, with the most integrated healthcare system in the country, is committed to provide lifelong comprehensive treatment to veterans with multiple sclerosis. Veterans should have access to the most cutting-edge and effective resources available since they have made important contributions to their nation.
Recently, Helius Medical spotlighted the personal narrative of Kevin Byrne, a retired U.S. veteran grappling with MS since 1999. Gait impairments had robbed him of cherished experiences with his 13-year-old daughter, yet PoNS Therapy aided in enhancing his walking abilities, including speed, endurance, and distance.
Following treatment with PoNS, he was able to accompany his daughter to New York City, where they relished strolling the streets and attending Broadway shows—experiences he believed were forever out of reach. While clinical data underscores the effectiveness of PoNS Therapy, firsthand testimonials such as Captain Byrne’s serve as the most rewarding validation of its impact.
